Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1Phase 2 1

Status

Completed 17Terminated 8Unknown 7Withdrawn 3Active not recruiting 3Recruiting 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Insulin Resistance 3Diabetes Mellitus, Type 2 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Pioglitazone × Clear all
NCT05098327 2023-08-15

Pioglitazone and Insulin Resistance in ADT

State University of New York at Buffalo

Phase 3 Withdrawn
Genitourinary

Diabetes Mellitus, Type 2, Insulin Resistance, Prostatic Neoplasms

NCT04995978 2023-06-23

Insulin Resistance and Androgen Deprivation Therapy

St. Louis University

Phase 2 Withdrawn
Genitourinary

Insulin Resistance, Prostatic Neoplasms

NCT04658849 2023-05-15

Insulin Resistance Following ADT for Prostate CA

St. Louis University

Phase EARLY_PHASE1 Withdrawn
Genitourinary

Insulin Resistance, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡